Business Wire

SES Selects Arianespace and Soyuz for its Fifth MEO Launch

Del

SES has selected Arianespace for its fifth launch of four O3b satellites joining its O3b Medium Earth Orbit (MEO) fleet. The mission on a Soyuz rocket will be conducted from the Guiana Space Center in Kourou, French Guiana, in 2019. The 12 satellites of the existing O3b fleet were orbited by Arianespace in 2013 and 2014; the next four satellites (13th to 16th) will be launched by Arianespace next year. The O3b fleet delivers low-latency data services provided by SES Networks, a business unit of SES.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170912005832/en/

SES Selects Arianespace and Soyuz for its Fifth MEO Launch (Photo: Business Wire)

SES Selects Arianespace and Soyuz for its Fifth MEO Launch (Photo: Business Wire)

The 20 O3b satellites that SES Networks positions and operates in MEO, nearly 8,000 kilometres above the Earth, form the first strong building block of a unique high-power, high-throughput fleet. They are built by Thales Alenia Space, have a mass of approximately 700 kilogram at lift-off and provide each a capacity of more than 10 Gigabits per second.

In addition, SES has announced, on 11 September 2017, the launch of a new super-powered terabit constellation and connectivity network system, O3b mPOWER, which will add another seven next generation Boeing satellites and comprehensive global ground system starting in 2021 and bringing the total number of O3b satellites by then to 27. SES’s MEO system will be fully integrated into its large fleet in Geostationary Earth Orbit (GEO).

“We are pleased that we can rely on proven partners to develop our O3b fleet,” said Steve Collar, CEO of SES Networks. “As the only MEO constellation in the world, the O3b fleet is a cornerstone of our strategy to serve fast-growing data markets with high-performance, fibre-equivalent connectivity virtually anywhere. Our commitment to Arianespace also underscores that SES continues to play a major role for the European space industry.”

Stéphane Israël, Arianespace's Chief Executive Officer, said: “I would like to thank SES for having chosen Arianespace a fifth time for the deployment of its broadband telecommunications network. Entrusting Arianespace with the launch of four additional O3b satellites is a true recognition of the reliability and the excellence of our launch service solutions. With this contract, we are proud to contribute to the extension of the O3b constellation, thus taking a step further in advancing world broadband connectivity with satellites and reducing the digital divide. More than ever, Arianespace is living up to its motto of using space for a better life on Earth.

SES Networks, a provider of global managed data services, is a new SES business unit comprised of the former O3b Networks and SES data business. With the only network solutions powered by the O3b fleet of MEO satellites, together with the reach of more than 50 GEO satellites, SES Networks enables high-performance communications for fixed data, mobility and government customers virtually anywhere.

Follow us on:

Social Media

Blog

Media Gallery

White Papers

About SES

SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in two key business units: SES Video and SES Networks. The company provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions. SES’s portfolio includes ASTRA, O3b and MX1, a leading media service provider that offers a full suite of innovative digital video and media services. SES is listed on the Euronext Paris and Luxembourg Stock Exchange (ticker: SESG). Further information available at: www.ses.com

About Arianespace

Arianespace uses space to make life better on Earth by providing launch services for all types of satellites into all orbits. It has orbited more than 550 satellites since 1980, using its family of three launchers, Ariane, Soyuz and Vega, from launch sites in French Guiana (South America) and Baikonur, Kazakhstan. Arianespace is headquartered in Evry, near Paris, and has a technical facility at the Guiana Space Center, Europe’s Spaceport in French Guiana, plus local offices in Washington, D.C., Tokyo and Singapore. Arianespace is a subsidiary of ArianeGroup, which holds 74% of its share capital, with the balance held by 17 other shareholders from the European launcher industry.

Contact information

SES
Markus Payer
Corporate Communications & PR
Tel. +352 710 725 500
Markus.Payer@ses.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31Pressemelding

Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch

New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00Pressemelding

AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23

New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20Pressemelding

AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute

Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11Pressemelding

The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other

Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn17.11.2017 16:20Pressemelding

Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking. “We continue to establish MRC as the one-stop shop for financing transitional real estate, including ground-up development deals like 200 Kent Avenue,” said Josh Zegen, Co-Founder and Managing Principal of MRC. “In this case, we’re working with a repeat MRC borrower who understands our ability to execute efficiently, given our firm’s up-to-the minute knowledge of local market conditions and non-bureaucratic approach to

Ncardia Announces Completion of €10.5M Investment Round17.11.2017 12:31Pressemelding

Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million series B financing round. The round was led by Épimède, a Belgium venture capital firm. Ncardia is a privately-held company with operations in Europe and the US, that produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes assay services for drug safety and efficacy testing. Additionally the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress h

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom